Correlation Between Richmond Vanadium and Telix Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Richmond Vanadium and Telix Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Richmond Vanadium and Telix Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Richmond Vanadium Technology and Telix Pharmaceuticals, you can compare the effects of market volatilities on Richmond Vanadium and Telix Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Richmond Vanadium with a short position of Telix Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Richmond Vanadium and Telix Pharmaceuticals.

Diversification Opportunities for Richmond Vanadium and Telix Pharmaceuticals

-0.73

Correlation Coefficient

Richmond Vanadium  Telix Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between Richmond and Telix is -0.73. Overlapping area represents the amount of risk that can be diversified away by holding Richmond Vanadium Technology and Telix Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Telix Pharmaceuticals and Richmond Vanadium is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Richmond Vanadium Technology are associated (or correlated) with Telix Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Telix Pharmaceuticals has no effect on the direction of Richmond Vanadium i.e., Richmond Vanadium and Telix Pharmaceuticals go up and down completely randomly.

Pair Corralation between Richmond Vanadium and Telix Pharmaceuticals

Assuming the 90 days trading horizon Richmond Vanadium Technology is expected to under-perform the Telix Pharmaceuticals. In addition to that, Richmond Vanadium is 2.81 times more volatile than Telix Pharmaceuticals. It trades about -0.09 of its total potential returns per unit of risk. Telix Pharmaceuticals is currently generating about 0.08 per unit of volatility. If you would invest  2,467  in Telix Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  302.00  from holding Telix Pharmaceuticals or generate 12.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Richmond Vanadium Technology  vs.  Telix Pharmaceuticals

Richmond Vanadium

Risk-Adjusted Performance

Very Weak

Over the last 90 days Richmond Vanadium Technology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Telix Pharmaceuticals

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Telix Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Richmond Vanadium and Telix Pharmaceuticals

The main advantage of trading using opposite Richmond Vanadium and Telix Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Richmond Vanadium position performs unexpectedly, Telix Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telix Pharmaceuticals will offset losses from the drop in Telix Pharmaceuticals' long position.

The idea behind Richmond Vanadium Technology and Telix Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.